Abstract:Abstract Background To explore the impact of gut microbiota diversity on the efficacy of immunotherapy combined with chemotherapy in esophageal squamous cell carcinoma (ESCC) patients, aiming to identify microbial markers for predicting treatment outcomes. Methods In this study, we prospectively enrolled patients diagnosed with locally advanced esophageal squamous cell carcinoma who were scheduled to undergo neoadjuvant immunotherapy combined with chemotherapy; stool specimens were collected before the first cycle, the second cycle of immunotherapy, and at the time of preoperative disease evaluation. To examine the gut microbiota's composition and abundance, we employed the 16S rDNA sequencing technique. The sequencing data were preprocessed with FLASH and Uparse software, and species annotation was performed using the SSUrRNA database. Microbiota analysis was conducted using the R language, and group differences were assessed using appropriate statistical methods. Results In this study, 43 patients (totally 122 stool samples) with neoadjuvant immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma were enrolled from December 2020 to January 2022. 16S rDNA sequencing results suggested that patients in the sensitive group had higher total fecal microbiota diversity than those in the drug-resistant group, and a notable variation in the structure of the microbiota was detected between the two groups. During treatment, the results did not show any significant statistical difference in the number of species (alpha diversity) in the sensitive group compared to the resistant group, although there was a trend towards a higher number of species in the pre-treatment sensitive group. As the treatment progressed, starting from the second cycle of treatment, the sensitive group had a higher alpha diversity than the resistant group. And we found that Bray-Curtis distance assessment of beta diversity showed that the difference between the sensitive and resistant groups also became more pronounced as treatment progressed. At the phylum level, the gut flora composition of the sensitive group remained relatively stable as treatment progressed, while the microbial diversity of the resistant group appeared to decrease. At the genus level, Bifidobacterium, Faecalibacterium, Akkermansia and Ruminococcus were more abundant in the immunotherapy-sensitive group; whereas Ligilactobacillus and Escherichia-Shigella was more rich in the immunotherapy-resistant group. The prediction model based on the baseline differences of gut microbiota in the two groups using a random forest method can be applied to predict the efficacy of immunotherapy for esophageal squamous cell carcinoma. Conclusion There are differences in species diversity and microbiota structure between the sensitive and resistant groups of esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemotherapy, and the predictive model, which is based on the microbiota differences between the two groups before treatment, could be clinically relevant in predicting the efficacy of immunotherapy combined with chemotherapy for esophageal squamous cell carcinoma.

Implications of intestinal microecology and immune function alterations for immunotherapy outcomes in advanced unresectable lung adenocarcinoma

Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory

Effect of hyperthermia on intestinal microecology, immune function, and progression-free survival in patients with advanced unresectable lung adenocarcinoma

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer

Prospective Correlation Between the Patient Microbiome with Response to and Development of Immune-Mediated Adverse Effects to Immunotherapy in Lung Cancer.

Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma

Efficacy of intestinal microorganisms on immunotherapy of non-small cell lung cancer

Relationship Between Intestinal Flora Structure and Metabolite Analysis and Immunotherapy Efficacy in Chinese NSCLC Patients

Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis

Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies

424. EFFECT OF GUT MICROBIOTA ON THE RESPONSE TO NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

A metagenome association study of gut microbiome revealed biomarkers for chemotherapy efficacy in locally advanced and advanced lung cancer

Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes

Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Microbiota: A key factor affecting and regulating the efficacy of immunotherapy

Modulation of the intestinal microbiota impacts the efficacy of immunotherapy in cancer patients – A recent literature survey